Close Menu

NEW YORK – Flow cytometry startup BennuBio has closed on $5 million of a $7 million Series B financing round, which it plans to use to expand commercial efforts, accelerate development of new features for its initial product, and develop additional complementary products.

The funding round was led by new investor Co-Win Ventures, with additional investment by existing investors Tramway Partners, Cottonwood Technology Fund, and Sun Mountain Capital. Xin Huang, managing partner at Co-Win Ventures, will also join BennuBio's board of directors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.